{"nctId":"NCT03893448","briefTitle":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)","startDateStruct":{"date":"2019-06-19","type":"ACTUAL"},"conditions":["Pneumococcal Infections","Pneumococcal Vaccines"],"count":1720,"armGroups":[{"label":"V114","type":"EXPERIMENTAL","interventionNames":["Biological: V114","Biological: RotaTeq™","Biological: Pentacel™","Biological: RECOMBIVAX HB™","Biological: VAQTA™","Biological: MMR II™","Biological: VARIVAX™","Biological: HIBERIX™"]},{"label":"Prevnar 13™","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Prevnar 13™","Biological: RotaTeq™","Biological: Pentacel™","Biological: RECOMBIVAX HB™","Biological: VAQTA™","Biological: MMR II™","Biological: VARIVAX™","Biological: HIBERIX™"]}],"interventions":[{"name":"V114","otherNames":["VAXNEUVANCE™","Pneumococcal 15-Valent Conjugate Vaccine"]},{"name":"Prevnar 13™","otherNames":[]},{"name":"RotaTeq™","otherNames":[]},{"name":"Pentacel™","otherNames":[]},{"name":"RECOMBIVAX HB™","otherNames":[]},{"name":"VAQTA™","otherNames":[]},{"name":"MMR II™","otherNames":[]},{"name":"VARIVAX™","otherNames":[]},{"name":"HIBERIX™","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Is healthy (based on a review of medical history and physical examination) in the clinical judgement of the investigator\n* Has a legally acceptable representative who understands the study procedures, alternate treatments available, and risks involved with the study and voluntarily agrees to participate by giving written informed consent.\n\nExclusion Criteria:\n\n* Has a history of invasive pneumococcal disease (IPD; positive blood culture, positive cerebrospinal fluid culture, or other sterile site) or known history of other culture positive pneumococcal disease.\n* Has a known hypersensitivity to any component of the pneumococcal conjugate vaccine (PCV), any component of the licensed pediatric vaccines to be administered concomitantly in the study, or any diphtheria toxoid-containing vaccine.\n* Has any contraindication to the concomitant study vaccines being administered in the study.\n* Had a recent febrile illness (rectal temperature ≥38.1°C \\[=100.5°F\\] or axillary temperature ≥37.8°C \\[=100.0°F\\]) occurring within 72 hours prior to receipt of study vaccine.","healthyVolunteers":true,"sex":"ALL","minimumAge":"42 Days","maximumAge":"90 Days","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Solicited Injection-Site Adverse Events (AEs) in V114 Versus Prevnar 13™","description":"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs consisted of swelling, redness, pain or tenderness, and hard lump.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.0","spread":null},{"groupId":"OG001","value":"69.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.7","spread":null},{"groupId":"OG001","value":"38.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","spread":null},{"groupId":"OG001","value":"26.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.8","spread":null},{"groupId":"OG001","value":"46.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","spread":null},{"groupId":"OG001","value":"24.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Solicited Systemic AEs","description":"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs consisted of irritability, drowsiness, appetite lost, and hives or welts.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.4","spread":null},{"groupId":"OG001","value":"84.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.3","spread":null},{"groupId":"OG001","value":"36.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.5","spread":null},{"groupId":"OG001","value":"75.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.0","spread":null},{"groupId":"OG001","value":"62.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null},{"groupId":"OG001","value":"6.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Vaccine-Related Serious Adverse Events (SAEs)","description":"An SAE is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an other important medical event. Any SAEs that are at least possibly related to vaccination are summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Anti-Pneumococcal Polysaccharide (Anti-PnP) Immunoglobulin G (IgG) Antibody (Ab) ≥0.35 ug/mL One Month After Vaccination 3","description":"Anti-PnP serotype-specific IgG response rates for the 15 serotypes contained in V114 were measured with pneumococcal electrochemiluminescence (PnECL). The percentage of participants with IgG Ab ≥0.35 ug/mL are reported for each serotype.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.7","spread":null},{"groupId":"OG001","value":"99.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.7","spread":null},{"groupId":"OG001","value":"79.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.4","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null},{"groupId":"OG001","value":"97.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.7","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.6","spread":null},{"groupId":"OG001","value":"92.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null},{"groupId":"OG001","value":"99.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.9","spread":null},{"groupId":"OG001","value":"97.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.4","spread":null},{"groupId":"OG001","value":"98.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.9","spread":null},{"groupId":"OG001","value":"99.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.5","spread":null},{"groupId":"OG001","value":"91.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"91.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.3","spread":null},{"groupId":"OG001","value":"91.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentration (GMC) of Anti-PnP IgG Ab One Month After Vaccination 3","description":"The GMC of anti-PnP IgG Ab were measured with PnECL one month after vaccination 3 and reported for the 15 serotypes contained in V114. IgG GMCs were compared to the lowest in recipients of Prevnar 13™ excluding serotype 3 for the 2 serotypes unique to V114, and compared to the same serotypes for the 13 shared serotypes.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.21","spread":null},{"groupId":"OG001","value":"1.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":null},{"groupId":"OG001","value":"0.62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.29","spread":null},{"groupId":"OG001","value":"1.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.63","spread":null},{"groupId":"OG001","value":"2.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.55","spread":null},{"groupId":"OG001","value":"2.95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.60","spread":null},{"groupId":"OG001","value":"1.97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.48","spread":null},{"groupId":"OG001","value":"3.23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.73","spread":null},{"groupId":"OG001","value":"1.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.78","spread":null},{"groupId":"OG001","value":"6.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.53","spread":null},{"groupId":"OG001","value":"2.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.63","spread":null},{"groupId":"OG001","value":"2.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.01","spread":null},{"groupId":"OG001","value":"2.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.31","spread":null},{"groupId":"OG001","value":"1.47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.91","spread":null},{"groupId":"OG001","value":"0.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.67","spread":null},{"groupId":"OG001","value":"0.06","spread":null}]}]}]},{"type":"PRIMARY","title":"GMC of Anti-PnP IgG Ab One Month After Vaccination 4","description":"The GMC of anti-PnP IgG Ab were measured with PnECL one month after vaccination 4 and reported for the 15 serotypes contained in V114. IgG GMCs were compared to the lowest in recipients of Prevnar 13™ excluding serotype 3 for the 2 serotypes unique to V114, and compared to the same serotypes for the 13 shared serotypes.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.35","spread":null},{"groupId":"OG001","value":"2.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":null},{"groupId":"OG001","value":"0.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.23","spread":null},{"groupId":"OG001","value":"1.60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.49","spread":null},{"groupId":"OG001","value":"3.95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.70","spread":null},{"groupId":"OG001","value":"6.21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.76","spread":null},{"groupId":"OG001","value":"6.43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.42","spread":null},{"groupId":"OG001","value":"4.85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.40","spread":null},{"groupId":"OG001","value":"3.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.61","spread":null},{"groupId":"OG001","value":"6.95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.62","spread":null},{"groupId":"OG001","value":"3.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.10","spread":null},{"groupId":"OG001","value":"5.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.55","spread":null},{"groupId":"OG001","value":"4.47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.04","spread":null},{"groupId":"OG001","value":"3.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.52","spread":null},{"groupId":"OG001","value":"0.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.15","spread":null},{"groupId":"OG001","value":"0.09","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Meeting Response Rate Criteria for Pentacel™-Specific (Anti-Diptheria Toxoid, Tetanus Toxoid, and Pertussis Antigens) Immunoglobulin G (IgG) Antibody (Ab) Geometric Mean Concentration (GMC) One Month After Vaccination 3","description":"Antibody responses to diphtheria toxoid, tetanus toxoid, and pertussis antigens were measured using Luminex Assay. The percentage of participants meeting specific criteria are summarized for each serotype. The serotype-specific response rate criteria are as follows: diphtheria toxoid: % ≥0.1 IU/mL; tetanus toxoid: % ≥0.1 IU/mL; pertussis toxin (PT): % ≥ 5 EU/mL; pertussis filamentous hemagglutinin (FHA): % ≥5 EU/mL; pertussis fimbrae types 2/3 (FIM 2/3): % ≥20 EU/mL; pertussis pertactin (PRN): % ≥5 EU/mL; poliovirus 1: % neutralizing antibody (NAb) ≥1:8 dilution; poliovirus 2: % NAb ≥1:8 dilution, poliovirus 3: % NAb ≥1:8 dilution; and Haemophilus influenzae Type B polyribosylribitol phosphate (Hib-PRP): % ≥0.15 ug/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.9","spread":null},{"groupId":"OG001","value":"97.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null},{"groupId":"OG001","value":"98.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.1","spread":null},{"groupId":"OG001","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.7","spread":null},{"groupId":"OG001","value":"61.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.3","spread":null},{"groupId":"OG001","value":"65.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.8","spread":null},{"groupId":"OG001","value":"99.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.1","spread":null},{"groupId":"OG001","value":"93.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Pertussis Antigen Immunoglobulin G (IgG) Antibody (Ab) Geometric Mean Concentration (GMC) One Month After Vaccination 3","description":"Pertussis antibody GMCs were measured using Luminex Assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.73","spread":null},{"groupId":"OG001","value":"44.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.51","spread":null},{"groupId":"OG001","value":"69.18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.79","spread":null},{"groupId":"OG001","value":"36.87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.16","spread":null},{"groupId":"OG001","value":"13.17","spread":null}]}]}]},{"type":"SECONDARY","title":"Hepatitis A Antibody Response Rate One Month After Vaccination 4","description":"Antibody response rates to hepatitis A were measured with hepatitis A virus enzyme immunoassay (HAV EIA). The percentage of participants with hepatitis A antigen ≥10 mIU/mL are reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.4","spread":null},{"groupId":"OG001","value":"97.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Measles, Mumps, and Rubella Antibody Response Rate One Month After Vaccination 4","description":"Antibody responses to measles were measured with the bulk measles IgG enzyme immunoassay (EIA). Antibody responses to mumps were measured with enzyme-linked immunosorbent assay (ELISA). Antibody responses to rubella were measured with Bulk Rubella IgG EIA. The percentage of participants with measles antigen ≥255 mIU/ML; mumps antigen ≥10 mumps Ab units/mL; and rubella antigen ≥10 IU/mL, are reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.1","spread":null},{"groupId":"OG001","value":"98.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.8","spread":null},{"groupId":"OG001","value":"97.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.1","spread":null},{"groupId":"OG001","value":"98.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Varicella-Zoster Virus (VZV) Antibody Response Rate One Month After Vaccination 4","description":"Antibody responses to varicella-zoster virus were measured with glycoprotein enzyme-linked immunosorbent assay (gpELISA). The percentage of participants with VZV antigen ≥5 gpELISA units/mL are reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.4","spread":null},{"groupId":"OG001","value":"97.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Haemophilus Influenzae Type B Antibody Response Rate One Month After Vaccination 4","description":"Antibody responses to Haemophilus influenzae Type B polyribosylribitol phosphate (Hib PRP) were measured with ELISA. The percentage of participants with anti-HiB PRP antigen ≥0.15 ug/mL are reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-Pneumococcal Polysaccharide (Anti-PnP) Serotype-Specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMC) One Month After Vaccination 3 for 2 Unique V114 Seroptypes","description":"Serotype-specific anti-PnP IgG GMCs for the 2 unique V114 serotypes were measured with PnECL. The GMCs for each serotype are reported.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.91","spread":null},{"groupId":"OG001","value":"0.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.67","spread":null},{"groupId":"OG001","value":"0.06","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-Pneumococcal Polysaccharide (Anti-PnP) Serotype-Specific Immunoglobulin G (IgG) Response Rates One Month After Vaccination 3 for 2 Unique V114 Seroptypes","description":"Serotype-specific anti-PnP IgG response rates for the 2 unique V114 serotypes were measured with PnECL. The percentage of participants with IgG Ab ≥0.35 ug/mL are reported for each serotype.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"3.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.3","spread":null},{"groupId":"OG001","value":"2.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-Pneumococcal Polysaccharide (Anti-PnP) Serotype-Specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMC) One Month After Vaccination 4 for 2 Unique V114 Seroptypes","description":"Serotype-specific anti-PnP GMCs were measured with PnECL. The GMC for each serotype is reported.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.52","spread":null},{"groupId":"OG001","value":"0.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.15","spread":null},{"groupId":"OG001","value":"0.09","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-Pneumococcal Polysaccharide (Anti-PnP) Serotype-Specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) One Month After Vaccination 3","description":"Serotype-specific anti-PnP OPA GMTs were measured with multiplex opsonophagocytic assay (MOPA). The GMTs for each serotype are summarized.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.9","spread":null},{"groupId":"OG001","value":"78.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"284.7","spread":null},{"groupId":"OG001","value":"210.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1304.8","spread":null},{"groupId":"OG001","value":"1566.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"387.4","spread":null},{"groupId":"OG001","value":"510.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2072.1","spread":null},{"groupId":"OG001","value":"2743.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1932.5","spread":null},{"groupId":"OG001","value":"1963.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4973.2","spread":null},{"groupId":"OG001","value":"7335.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1217.3","spread":null},{"groupId":"OG001","value":"1534.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2400.7","spread":null},{"groupId":"OG001","value":"1853.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1171.2","spread":null},{"groupId":"OG001","value":"1330.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"841.3","spread":null},{"groupId":"OG001","value":"1400.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"703.9","spread":null},{"groupId":"OG001","value":"850.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2078.9","spread":null},{"groupId":"OG001","value":"3668.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1849.3","spread":null},{"groupId":"OG001","value":"9.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8262.6","spread":null},{"groupId":"OG001","value":"119.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-Pneumococcal Polysaccharide (Anti-PnP) Serotype-Specific Opsonophagocytic Activity (OPA) Response Rates One Month After Vaccination 3","description":"Serotype-specific anti-PnP OPA GMTs were measured with MOPA. The percentage of participants meeting ≥0.35 ug/mL are reported for each serotype.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.5","spread":null},{"groupId":"OG001","value":"87.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.5","spread":null},{"groupId":"OG001","value":"98.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null},{"groupId":"OG001","value":"98.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null},{"groupId":"OG001","value":"98.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null},{"groupId":"OG001","value":"97.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":null},{"groupId":"OG001","value":"98.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":null},{"groupId":"OG001","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null},{"groupId":"OG001","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.9","spread":null},{"groupId":"OG001","value":"98.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","spread":null},{"groupId":"OG001","value":"5.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":null},{"groupId":"OG001","value":"56.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-Pneumococcal Polysaccharide (Anti-PnP) Serotype 3-Specific Immunoglobulin G (IgG) Response Rate One Month After Vaccination 3","description":"Serotype 3-specific anti-PnP IgG response rates were measured with PnECL. The percentage of participants with IgG Ab ≥0.35 ug/mL are reported for Serotype 3.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.7","spread":null},{"groupId":"OG001","value":"79.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-Pneumococcal Polysaccharide (Anti-PnP) Serotype 3-Specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMC) One Month After Vaccination 3","description":"Serotype 3-specific anti-PnP GMC was measured with PnECL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":null},{"groupId":"OG001","value":"0.62","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-Pneumococcal Polysaccharide (Anti-PnP) Serotype 3-Specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMC) One Month After Vaccination 4","description":"Serotype 3-specific anti-PnP GMC were measured with PnECL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":null},{"groupId":"OG001","value":"0.71","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":88,"n":858},"commonTop":["Irritability","Somnolence","Injection site pain","Injection site erythema","Decreased appetite"]}}}